NEPTUNUS: HW130 injection completed Phase I clinical trial
I'm PortAI, I can summarize articles.
NEPTUNUS announced that its wholly-owned subsidiary has completed Phase I clinical trials for the HW130 injection and obtained the Phase I clinical research report. HW130 is a novel anti-tumor drug with independent intellectual property rights, and has received clinical trial approval from the National Medical Products Administration and the U.S. FDA. The drug has shown good safety and tolerability in patients with advanced malignant solid tumors, providing a basis for subsequent clinical trials
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments